A mother and daughter share a unique therapy experience as graduate student helps her mother navigate communication ...
Lipoic acid offers no improvements in walking speed or other outcomes in patients with progressive multiple sclerosis ...
—Data from this real-world study revealed that patients with MS being treated with DMTs had a disproportionally higher number of cases of herpes zoster compared with patients treated with other ...
Dr. Parisa Khosravi knows exactly what her patients are going through and the shock they might experience when she delivers the diagnosis. As a neuroimmunologist at Central Texas Neurology Consultants ...
Zacks Investment Research on MSN
FDA issues CRL to SNY's regulatory filing for multiple sclerosis drug
Sanofi SNY announced that the FDA has issued a complete response letter (CRL) to its new drug application (NDA), seeking ...
An American neurologist and an Italian epidemiologist whose work revolutionized the treatment of multiple sclerosis have won ...
Annual out-of-pocket treatment costs for multiple sclerosis increased by 125% from 2002 to 2021 in the US, driven mainly by ...
Multiple sclerosis (MS) is a chronic autoimmune disease characterized by the disruption of nerve signals and various ...
Sanofi’s multiple sclerosis hopeful tolebrutinib faced dual setbacks on Monday, with a late-stage failure in one form of the disease and yet another regulatory setback in another.
Sanofi will conduct an impairment test in accordance with IFRS (IAS 36) on the intangible asset value attached to tolebrutinib with a status to be provided with Q4 and FY 2025 results in January 2026.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback